

ACRONYM	MEANING
ADC	Antibody-Drug Conjugate
Allo	Allogeneic Stem Cell Transplant
Auto	Autologous Stem Cell Transplant
ASCT	Autologous Stem Cell Transplant
β2M, β2M	Beta-2 Microglobulin
BCMA	B-cell Maturation Antigen
BiRd	Biaxin + Revlimid + Dexamethasone
BiTE	Bispecific T-cell Engagers
BMT CTN	Bone Marrow Transplant Clinical Trials Network
BP	Bisphosphonate
CALGB	Cancer and Leukemia Group B (a US cooperative clinical trials group)
CAR T	Chimeric Antigen Receptor (CAR T-cell therapy)
CBC	Complete Blood Count
CD34	Cluster of Differentiation 34 (a cell surface protein on hemtopoietic stem cells)
CD38	Cluster of Differentiation 38 (a cell surface protein on hematopoietic stem cells)
CI	Confidence Interval (statistical term)
CR	Complete Response/Remission
Cr	Creatinine
CRAB	C alcium R enal A nemia B one Disease
CRP	C-reactive Protein
CRS	Cytokine Release Syndrome
CT	Computerized Tomography Scan (3D X-ray)
CyBorD	C ytotoxan + V elcade (b ortezomib) + D examethasone
DCEP	D examethasone + C yclophosphamide + E toposide + C isplatin
DEX	Dexamethasone
D-PACE	D examethasone + C isplatin + A driamycin + C yclophosphamide + E toposide
DVD	Doxil + Vincristine + Dexamethasone

DVT	Deep Vein Thrombosis
EFS	Event Free Survival
EMD	Extramedullary Disease (myeloma that grows outside the bone marrow)
FISH	Fluorescence In Situ Hybridization
FLC	Free Light Chain (kappa or lambda)
GEP	Gene Expression Profile
GIMEMA	The Italian myeloma clinical trials group
GMMG	The German myeloma clinical trials group
GVHD	Graft-versus-Host Disease
HDAC	Histone Deacetylase
ACRONYM	MEANING
HDT	High-Dose Therapy
HOVON	The Dutch clinical trials myeloma group
HR	Hazard Ratio (statistical term)
HRSM	High-Risk Smoldering Multiple Myeloma (high-risk features include t(4;14), t(14;16), 17p-, 1q+)
IEP	Immuno-electrophoresis
IFE	Immunofixation Electrophoresis
Ig	Immunoglobulin
IM	Intramuscular (shot or injection into the muscle)
ISS	International Staging System
IV	Intravenous (injection into the vein)
IVIG	Intravenous Immunoglobulins
KRD	Kyprolis (carfilzomib) + Revlimid (lenalidomide) + Dexamethasone
MEL 200	The dose of melphalan administered in ASCT: 200 mg of melphalan per square meter of body mass
MGUS	Monoclonal Gammopathy of Undetermined Significance
MP	Melphalan + Prednisone
MPR	Melphalan + Prednisone + Revlimid (lenalidomide)
MPT	Melphalan + Prednisone + Thalidomide

MR	Minimal Response (between 25% and 50% response to a drug or regimen in a clinical trial)
MRC	Medical Research Council (UK myeloma clinical trials group)
MRD	Minimal Residual Disease
MRI	Magnetic Resonance Imaging
mSMART	M ayo S tratification of M yeloma and R isk-Adapted T herapy
MTD	Maximum-tolerated Dose
NA or N/A	Not Available
nCR	Near-Complete Response
NDMM	Newly Diagnosed Multiple Myeloma
NGF	Next-Generation Flow (new 8-color flow cytometry test with software for myeloma)
NGS Nex	Next-Generation Sequencing (new DNA-sequencing test)
NR	Not Reached
ONJ	Osteonecrosis of the Jaw
ORR	Overall Response Rate
OS	Overall Survival
PAD	Velcade (formerly PS-341) + A driamycin + D examethasone
PBSCT	Peripheral Blood Stem Cell Transplant
PCLI	Plasma Cell Labeling Index
PCR	Polymerase Chain Reaction (DNA test, also called ASO PCR or Aleele-Specific Oligonucleotide PCR)
ACRONYM	MEANING
PET	Positron Emission Tomography
PET/CT	PET combined with a CT scan
PETHEMA	The Spanish myeloma clinical trials group
PFS	Progression-Free Survival
PN	Peripheral Neuropathy
PR	Partial Remission/Partial Response
REVLodeX	Rev limid (lenalidomide) + L ow dose D examethasone
R-ISS	Revised International Staging System

RMPT	Revlimid (lenalidomide) + Melphalan + Prednisone + Thalidomide
RRMM	Relapsed/Refractory Multiple Myeloma
RQPCR	Real-time Quantitative Polymerase Chain Reaction (DNA test)
RVD	Revlimid (lenalidomide) + Velcade (bortezomib) + Dexamethasone
sCR	Stringent Complete Response (CR plus normal free light chain ratio and no clonal plasma cells)
SCT	Stem Cell Transplant (aka High-Dose Therapy with Stem Cell Rescue)
SD	Stable Disease
SINE compound	Selective Inhibitor of Nuclear Export, or SINE compound
SMM	Smoldering Multiple Myeloma
SPM	Second Primary Malignancy
SQ	Subcutaneous (also abbreviated as SC)
SRE	Skeletal-related Event
TMI	Too Much Information
TTP	Time to Progression
VAD	Vincristine + Adriamycin + Dexamethasone (old standard induction therapy)
VAMP	Vincristine + Adriamycin + Methylprednisolone
VCF	Vertebral Compression Fracture
VDT-PACE	Velcade + Dexamethasone + Thalidomide + Cisplatin + Adriamycin + Cyclophosphamide + Etoposide
VEGF	Vascular Endothelial Growth Factor
VGPR	Very Good Partial Remission
VRd	Velcade + Revlimid + Low-dose Dexamethasone
VTD	Velcade + Thalidomide + Dexamethasone
WBLD CT	Whole-Body Low-Dose CT
WBLD MRI	Whole-Body Low-Dose MRI
XGeva	Denosumab
ZOL	Zoledronic acid (Zometa®)